Perform Another (Advanced) Search

1.  Study Posting (2348) Trial #72352, HIV, New York, NY
...Study Posting (2348) Trial #72352, HIV, New York, NY Trial Information Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects with Hepatic Impairment The purpose of this study is to show the safety of Efavirenz (Sustiva) in HIV-1 infected patients as well as to see how it works in ...
View Page

2.  News: Pfizer HIV Treatment Sees Positive Results (Clinical Trials Today)
...maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never ...
...used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine. In ...
View Page

3. Clinical Trial Results by Drug Names
...II Trial Assessing 3 Doses of T-20 in Combination with Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-Infected Adults Fast Facts: Protocol number: T20-206 Sponsor: Trimeris Inc; Hoffmann-La ...
...PK) of T-20 (Fuzeon) in combination with Abacavir (ABC), Amprenavir (APV), Ritonavir (RTV), and Efavirenz (EFV) in Human Immunodeficiency Virus Type-1 ( HIV-1) infected adults. Study center(s) : 15 ...
View Page

4.  CenterWatch: New Medical Therapies in Disease Category (179), HIV Infections
...maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never ...
...used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine. In ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (417), HIV
...received Isentress administered orally twice daily in combination with tenofovir and lamivudine or 600 mg efavirenz (dosed orally once daily in combination with the same agents. During the first 48 weeks ...
...subjects on the Isentress combined regimen was approximately 55,000 copies/mL and for the efavirenz regimen was approximately 68,000 copies/mL. Mean baseline CD4 cell counts were 305 and ...
View Page

6.  Study Posting (2348) Trial #44075, HIV, New York, NY
...more frequent initial HAART regimen to a once daily regimen including stavudine XR, lamivudine and efavirenz. Bristol Myers Squibb has begun this research study of an experimental drug called stavudine (d4T/Zerit) Extended Release (XR) to be taken in combination with lamivudine (3TC/Epivir) and efavirenz (EFV/Sustiva) in once daily therapy. The purpose of this study is to find out ...
View Page

7. Clinical Trial Results: HIV Infections
...II Trial Assessing 3 Doses of T-20 in Combination with Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-Infected Adults Product Name: Fuzeon [enfuvirtide] Date of Report: 10/8/2001 Phase ...
View Page

8. Advanced/Specific Search Results Fuzeon [enfuvirtide]
...II Trial Assessing 3 Doses of T-20 in Combination with Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-Infected Adults Product Name: Fuzeon [enfuvirtide] Date of Report: 10/8/2001 Phase ...
View Page

9.  Newly Approved Drug Therapies (835) Reyataz (atazanavir sulfate), Bristol-Myers Squibb,
...first (study AI424-034) was a randomized, double-blind, multicenter trial comparing Reyataz (400mg) to efavirenz (600mg) once daily, each in combination with fixed-dose lamivudine (150) + zidovudine (300mg) twice daily ...
...Reyataz plus lamivudine/zidovudine group responded to treatment compared with 62% of subjects in the efavirenz plus lamivudine/zidovudine group. Response was based on subjects that achieved and maintained confirmed HIV ...
View Page

10.  CenterWatch: New Medical Therapies in Disease Category (803), Idiopathic Thrombocytopenic Purpura (ITP)
...type HIV-1 virus. The subjects received 10 mg/day elvucitabine with 600 mg/day efavirenz and 300 mg/day tenofovir or 300 mg/day 3TC with 600 mg/day efavirenz and 300 mg/day tenofovir. The study included a twelve-week blinded treatment period after ...
View Page

11.  CenterWatch: New Medical Therapies in Disease Category (2), AIDS and AIDS related infections
...maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never ...
...used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine. In ...
View Page

12.  CenterWatch: New Medical Therapies in Disease Category (703), HIV/AIDS
...received three once-daily doses of TMC278 (25 mg, 75 mg, and 150 mg) or efavirenz (600 mg) both in combination with Combivir or Truvada. At 48 weeks 81% (25mg), 80% ...
...load <50 copies/mL. This was also reached by 81% of the subjects in the efavirenz arm. Based on the results, Tibotec plans to use the 75 mg dose for upcoming ...
View Page

13.  News: Merck's Isentress Results Positive (Clinical Trials Today)
...received Isentress administered orally twice daily in combination with tenofovir and lamivudine or 600 mg efavirenz, dosed orally once daily in combination with the same agents. ... BlogCategory: Clinical Trial Results, ...
View Page

14.  CenterWatch: New Medical Therapies in Disease Category (372), Vaccines
...maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never ...
...used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine. In ...
View Page

15.  CenterWatch: New Medical Therapies in Disease Category (182), Influenza
...maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never ...
...used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine. In ...
View Page

16.  CenterWatch: New Medical Therapies in Disease Category (670), Hepatitis C; Chronic
...mg; each administered orally twice daily) in combination with tenofovir and lamivudine or 600 mg efavirenz dosed orally once daily in combination with the same agents. The trial was designed to compare Isentress to efavirenz in terms of sustained reductions in HIV viral RNA and improvements in CD4 cell counts ...
View Page

17.  Newly Approved Drug Therapies (959) Selzentry (maraviroc), Pfizer,
...300 mg twice daily. Selzentry plus CYP3A inducers (without a strong CYP3A inhibitor) These include: • efavirenz • rifampin • carbamazepine, phenobarbital, and phenytoin The recommended initial dose of Selzentry is 600 mg twice ...
View Page

18.  CenterWatch: Clinical Trials in Category (417) HIV
...247: A New Investigational Anti-HIV Drug New York : Mount Sinai Medical Center Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects with Hepatic Impairment New York : The Rockefeller University ...
...more frequent initial HAART regimen to a once daily regimen including stavudine XR, lamivudine and efavirenz. Rochester : University of Rochester School of Medicine HIV positive? Interested in an investigational vaccine for ...
View Page

19.  Study Posting (1918) Trial #158907, Lung Cancer, Savannah, GA
...any of the following: • Rifampin • Rifabutin • Carbamazepine • Phenobarbital • Phenytoin • Hypericum perforatum (St. John's wort) • Efavirenz • Tipranavir • No concurrent agents with proarrhythmic potential, including any of the following: • Quinidine • Procainamide • Disopyramide ...
View Page

20.  Study Posting (1918) Trial #159848, Lung Cancer, Savannah, GA
...any of the following: • Rifampin • Rifabutin • Carbamazepine • Phenobarbital • Phenytoin • Hypericum perforatum (St. John's wort) • Efavirenz • Tipranavir • No concurrent therapeutic doses of coumarin-derivative anticoagulants • Doses ≤ 2 mg daily for prophylaxis ...
View Page